{
    "clinical_study": {
        "@rank": "34952", 
        "arm_group": [
            {
                "arm_group_label": "liraglutide plus insulin", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Insulin titration only", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the effect of adding liraglutide to high dose\n      insulin therapy compared to high dose insulin therapy alone in patients with insulin-treated\n      Type 2 diabetes with insulin requirements of > 100 units of insulin per day."
        }, 
        "brief_title": "Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type II", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "40 subjects with Type 2 diabetes using > 100 units of insulin per day with or without\n      metformin with HbA1c > 6.5% will be randomized into 2 treatment groups: treatment group will\n      have liraglutide added to insulin and control group will have insulin uptitration only for 6\n      months.  Primary endpoint to be compared between groups will be HbA1c at 6 months.\n      Secondary endpoints will include weight, total daily insulin dose, percent time in\n      euglycemic, hyperglycemic, and hypoglycemic ranges by continuous glucose monitor (CGM), and\n      effect on GlycoMark and hs-CRP.  Safety endpoints will include incidence of hypoglycemia and\n      incidence of gastrointestinal side effects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male and female patients with Type 2 diabetes with HbA1c from 6.5 to 10% treated with\n             intensive insulin therapy (MDI or CSII, including U-500 insulin-treated patients)\n             using > 100 units of insulin, with or without a stable dose of oral insulin\n             sensitizing medications, for at least three months.\n\n          2. Aged 18 to 80 years.\n\n          3. Females of child-bearing potential must be using adequate form of contraception.\n\n          4. Patient willing to monitor BG four times daily, use CGM, and comply with\n             study-related protocol.\n\n        Exclusion Criteria:\n\n          1. Type 1 diabetes.\n\n          2. Use of any GLP-1 receptor agonist within previous three months.\n\n          3. Use of DPP-4 inhibitors or oral insulin secretagogues within the previous three\n             months.\n\n          4. Use of glucocorticoids (except inhaled).\n\n          5. Use of any experimental drug within previous three months.\n\n          6. Known or suspected allergy to liraglutide, Novolog or Levemir.\n\n          7. Personal or family history of medullary carcinoma of the thyroid or MEN-2.\n\n          8. Concomitant chronic renal disease with creatinine > 1.5%.\n\n          9. Concomitant chronic hepatic, gastrointestinal or other illness (including\n             pancreatitis or active cardiovascular disease except stable exertional angina).\n\n         10. Inability or unwillingness to monitor BG, use CGM, or comply with study protocol.\n\n         11. Women of child-bearing potential unwilling to use adequate contraception, intending\n             to become pregnant or breast-feeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2011", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01654120", 
            "org_study_id": "high dose and lira 001"
        }, 
        "intervention": [
            {
                "arm_group_label": "liraglutide plus insulin", 
                "description": "SC, 1.8mg,QD, six months to one year", 
                "intervention_name": "Liraglutide", 
                "intervention_type": "Drug", 
                "other_name": "Victoza"
            }, 
            {
                "arm_group_label": [
                    "liraglutide plus insulin", 
                    "Insulin titration only"
                ], 
                "description": "SC, will be titrated during the study, 4 times a day, 1 year", 
                "intervention_name": "Insulin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "U-500", 
                    "Levemir", 
                    "Novolog"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin", 
                "Glucagon-Like Peptide 1"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "insulin", 
            "Type II Diabetes", 
            "liraglutide", 
            "Glucagon-Like Peptide 1"
        ], 
        "lastchanged_date": "November 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Asheville", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "28803"
                }, 
                "name": "Mountain Diabetes and Endocrine Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Liraglutide and Insulin-001 A Randomized Prospective Trial of Liraglutide Added to High-Dose Insulin Therapy vs. High-Dose Insulin Therapy Alone in Insulin-Resistant Patients With Type 2 Diabetes", 
        "overall_official": {
            "affiliation": "Mountain Diabetes and Endocrine Center", 
            "last_name": "Wendy S Lane, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Glycemic control as measured by HbA1c", 
            "measure": "Change from baseline in HbA1c at six months", 
            "safety_issue": "No", 
            "time_frame": "baseline and six months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01654120"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The frequency and severity of hypoglycemia in each treatment arm by glucose meter download and by percent time spent in the hypoglycemic range (BG < 70 mg/dl) by CGM will be assessed at six and 12 months", 
                "measure": "Hypoglycemia", 
                "safety_issue": "Yes", 
                "time_frame": "6 months and 12 months"
            }, 
            {
                "description": "TDID will be determined in each treatment arm for statistical comparisons at three and six months, and for entire cohort at nine and 12 months.", 
                "measure": "Total Daily Insulin Dose (TDID)", 
                "safety_issue": "No", 
                "time_frame": "3, 6, 9, and 12 months"
            }, 
            {
                "description": "Weight will be statistically compared to baseline and between treatment arms at three and six months, and for entire cohort between baseline, six, nine and 12 months.", 
                "measure": "Weight", 
                "safety_issue": "No", 
                "time_frame": "baseline, 3, 6, 9, and 12 months"
            }, 
            {
                "description": "Postprandial glycemic control as assessed by GlycoMark and CGM will be compared between study groups at three and six months, and for entire cohort compared to baseline at nine and 12 months.", 
                "measure": "GlycoMark", 
                "safety_issue": "No", 
                "time_frame": "baseline, 3, 6, 9, and 12 months"
            }
        ], 
        "source": "Mountain Diabetes and Endocrine Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mountain Diabetes and Endocrine Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}